Aptuit, an Evotec company, is a pharmaceutical services provider that offers the most complete set of integrated early discovery to mid-phase drug development solutions by applying scientific excellence, outstanding service and a team of some of the foremost scientific professionals in the industry. These drug discovery and development professionals offer proven experience in key therapeutic areas. They share a legacy of success, having advanced a large number of molecules efficiently, expeditiously and economically, from early discovery through clinical development with low attrition rates. It is our uncommon expertise that allows Aptuit to identify the unexpected, mitigating risks and maximizing promising possibilities, ensuring exceptional results through an open, transparent climate of trust that our clients can count on. Our set of services include Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, and Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery and development services are available from our facilities in the US and Europe.
Looking for a particular Aptuit employee's phone or email?
The Aptuit annual revenue was $100 million in 2026.
Fabrizio Micheli is the VP, Medicinal Chemistry of Aptuit.
495 people are employed at Aptuit.
The NAICS codes for Aptuit are [32541, 54, 325, 5417, 3254, 32, 541].
The SIC codes for Aptuit are [372, 37].